
CAS · 137525-51-0
BPC-157 + TB-500 Blend 20mg
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.

Plate № PG-1030 — Reykjavík
Figure i · CJC-1295 No DAC 10mg — lyophilized plate
№ 01 — Monograph
CJC-1295 (No DAC) + Ipamorelin — pre-blended GHRH analog and ghrelin receptor agonist. Synergistic GH secretagogue combination producing amplified pulsatile growth hormone release.
Priced from
$71.99
Purity
≥ 98%
HPLC verified
Form
Lyophilized
Sealed vial
Ship
2–5 days
US, tracked
№ 02 — Specifications
CAS · 863288-34-0№ 03 — Mechanism
This combination pairs CJC-1295 No DAC (a GHRH analogue, also known as Mod GRF 1-29) with Ipamorelin (a selective ghrelin receptor agonist). CJC-1295 No DAC binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and secretion with a ~30 minute half-life that preserves pulsatile GH release. Ipamorelin (CAS: 170851-70-4) selectively activates GHS-R1a (ghrelin receptor) — a completely different receptor from the GHRH receptor. The dual-receptor activation (GHRH-R via CJC-1295, GHS-R1a via Ipamorelin) is additive: combined GH release substantially exceeds either compound alone. Ipamorelin's key advantage: unlike GHRP-2 or GHRP-6, it does not stimulate cortisol, prolactin, or ACTH release at research doses. The No DAC formulation's ~30 minute half-life preserves physiological pulsatile GH patterns vs the 6–8 day half-life of DAC-modified CJC-1295.
№ 04 — Highlights
GHRH receptor activation (CJC-1295) and ghrelin receptor activation (Ipamorelin) signal through different G-protein pathways (Gs and Gq respectively). Co-activation of both pathways in pituitary somatotrophs produces substantially greater GH pulse amplitude than either alone — the pharmacological rationale for the pre-blended combination.
Ipamorelin activates GHS-R1a with high selectivity, producing GH release without significant cortisol, ACTH, or prolactin elevation — unlike GHRP-2 and GHRP-6. At doses up to 10x standard research doses, Ipamorelin does not produce measurable off-target hormone stimulation.
The No DAC formulation of CJC-1295 has a ~30 minute half-life, allowing natural GH pulse rhythm to be maintained. The DAC modification extends half-life to 6–8 days, producing continuous GH elevation that blunts natural pulsatility. No DAC is specifically chosen for research requiring physiological GH pulsatile patterns.
№ 05 — Correspondence
The letters we receive most frequently about this compound, with plain answers.
CJC-1295 No DAC has ~30 minute half-life and produces discrete GH pulses. CJC-1295 with DAC has a Drug Affinity Complex modification enabling albumin binding, extending half-life to ~8 days for sustained GH elevation. No DAC better preserves physiological GH pulsatility.
GHRH receptor agonists (CJC-1295) and ghrelin receptor agonists (Ipamorelin) activate two independent intracellular pathways. This dual stimulation of pituitary somatotrophs produces substantially greater GH pulse amplitude than either compound alone.
Unlike GHRP-6 and GHRP-2, Ipamorelin is highly selective for GHS-R1a and does not significantly elevate ACTH or cortisol at research doses. This selectivity makes it the preferred ghrelin receptor agonist for clean GH secretagogue research.
Laboratory Use Only. This compound is sold for in-vitro laboratory research and is not intended for human consumption, injection, or therapeutic use. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with applicable regulations in their jurisdiction.
№ 06 — From the catalog

CAS · 137525-51-0
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
CJC-1295 No DAC 10mg
$71.99